Hologic (HOLX) Stock Drops Despite Market Gains: Important Facts to Note

14.01.25 23:45 Uhr

Werte in diesem Artikel
Aktien

59,50 EUR -1,00 EUR -1,65%

1.909,00 JPY -500,00 JPY -20,76%

Indizes

6.114,6 PKT -0,4 PKT -0,01%

Hologic (HOLX) closed the most recent trading day at $70.20, moving -0.13% from the previous trading session. This change lagged the S&P 500's daily gain of 0.12%. Meanwhile, the Dow experienced a rise of 0.52%, and the technology-dominated Nasdaq saw a decrease of 0.23%.The medical device maker's shares have seen a decrease of 2.97% over the last month, not keeping up with the Medical sector's loss of 2.25% and outstripping the S&P 500's loss of 3.45%.Analysts and investors alike will be keeping a close eye on the performance of Hologic in its upcoming earnings disclosure. The company's earnings report is set to go public on February 5, 2025. It is anticipated that the company will report an EPS of $1.01, marking a 3.06% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $1.03 billion, up 1.39% from the year-ago period.For the full year, the Zacks Consensus Estimates project earnings of $4.28 per share and a revenue of $4.17 billion, demonstrating changes of +4.9% and +3.48%, respectively, from the preceding year.Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Hologic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.16% fall in the Zacks Consensus EPS estimate. Hologic presently features a Zacks Rank of #3 (Hold).In the context of valuation, Hologic is at present trading with a Forward P/E ratio of 16.43. For comparison, its industry has an average Forward P/E of 28.11, which means Hologic is trading at a discount to the group.Also, we should mention that HOLX has a PEG ratio of 2.39. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Instruments industry was having an average PEG ratio of 2.06.The Medical - Instruments industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 77, positioning it in the top 31% of all 250+ industries.The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.Free: 5 Stocks to Buy As Infrastructure Spending SoarsTrillions of dollars in Federal funds have been earmarked to repair and upgrade America’s infrastructure. In addition to roads and bridges, this flood of cash will pour into AI data centers, renewable energy sources and more.In, you’ll discover 5 surprising stocks positioned to profit the most from the spending spree that’s just getting started in this space.Download How to Profit from the Trillion-Dollar Infrastructure Boom absolutely free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Hologic

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Hologic

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Hologic IncShs

Wer­bung

Analysen zu Hologic IncShs

DatumRatingAnalyst
01.08.2019Hologic BuyNeedham & Company, LLC
02.05.2019Hologic BuyNeedham & Company, LLC
31.01.2019Hologic BuyNeedham & Company, LLC
09.10.2018Hologic NeutralUBS AG
01.08.2018Hologic BuyNeedham & Company, LLC
DatumRatingAnalyst
01.08.2019Hologic BuyNeedham & Company, LLC
02.05.2019Hologic BuyNeedham & Company, LLC
31.01.2019Hologic BuyNeedham & Company, LLC
01.08.2018Hologic BuyNeedham & Company, LLC
03.05.2018Hologic BuyNeedham & Company, LLC
DatumRatingAnalyst
09.10.2018Hologic NeutralUBS AG
03.05.2018Hologic HoldCanaccord Adams
03.08.2017Hologic Sector PerformRBC Capital Markets
28.04.2016Hologic HoldNeedham & Company, LLC
07.01.2016Hologic Equal WeightBarclays Capital
DatumRatingAnalyst
30.07.2015Hologic UnderweightBarclays Capital
07.01.2015Hologic UnderweightBarclays Capital

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Hologic IncShs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"